We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Tempus AI Inc | NASDAQ:TEM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.86 | 1.64% | 53.26 | 53.00 | 53.80 | 3,809 | 11:42:26 |
From May 2024 to Nov 2024
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024, and provided recent business highlights.
“We continue to make great progress in deploying technology within healthcare as providers and life science companies are increasingly seeking AI solutions,” said Eric Lefkofsky, Founder and CEO of Tempus. “Given our expansive multimodal dataset, and our broad reach across thousands of connected healthcare providers, we are uniquely positioned to advance AI in diagnostics and accelerate the pace of algorithmic insights.”
Second Quarter 2024 Financial Results
Three Months Ended June 30,
2024
2023
Change
(in thousands, except percentages)
GAAP Results
Revenue
$
165,969
$
132,417
25.3%
Genomics gross margin
39.2%
48.9%
NM(1)
Data and services gross margin
58.7%
65.9%
NM(1)
Operating expenses
$
609,005
$
116,787
NM(1)
Net loss
$
(552,212)
$
(55,832
)
NM(1)
Non-GAAP Results
Non-GAAP Genomics gross margin
49.4%
48.9%
50 bps
Non-GAAP Data and services gross margin
72.4%
65.9%
650 bps
Non-GAAP Operating Expenses
$
134,742
$
116,787
15.4%
Adjusted EBITDA
$
(31,186)
$
(36,967)
15.6%
_______________
(1) Not meaningful due to the impact of including stock compensation expense and related employer payroll taxes
Recent Operating Highlights
Financial Outlook and Guidance
Tempus expects full year 2024 revenue of approximately $700 million, which represents approximately 32% year-over-year growth. The Company expects approximately ($105 million) in adjusted EBITDA, an improvement of approximately $50 million over 2023.
Webcast and Conference Call Information
A conference call and webcast will begin today, August 6, 2024 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:
Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/75k462fh
The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Non-GAAP Financial Measures
In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures.
Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”). Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue. Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments. Non-GAAP net income (loss) is defined as net income (loss), adjusted to exclude (i) losses on equity method investments, (ii) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, and (iv) the payment of $2.3 million of our Series G-4 convertible preferred stock in connection with the initial public offering (the “G-4 Special Payment”). Non-GAAP net income (loss) per share is defined as adjusted net income (loss) divided by weighted average common shares outstanding, basic and diluted.
Adjusted EBITDA is defined as net income (loss), adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses on equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) the stock-based compensation adjustments, and (Viii) the G-4 Special Payment. Adjusted EBITDA margin is calculated as adjusted EBITDA as a percentage of revenue.
Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.
Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between its forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net income and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods and could significantly impact future financial results.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for full year 2024; the contributions of Tempus’ research and findings to the larger scientific community and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Final Prospectus filed with the Securities and Exchange Commission (“SEC”) on June 17, 2024, pursuant to Rule 424(b)(4) under the Securities Act, as well as in other filings Tempus may make with the SEC in the future, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Tempus AI, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended June 30, Six Months Ended June 30,
2024
2023
2024
2023
Net revenue Genomics
$
112,324
$
91,924
$
214,893
$
173,982
Data and services
53,645
40,493
96,896
74,059
Total net revenue
$
165,969
$
132,417
$
311,789
$
248,041
Cost and operating expenses Cost of revenues, genomics
68,324
46,961
121,159
92,241
Cost of revenues, data and services
22,132
13,807
37,420
25,200
Technology research and development
77,908
23,427
104,975
46,329
Research and development
68,025
22,171
92,365
43,034
Selling, general and administrative
463,072
71,189
542,636
140,236
Total cost and operating expenses
699,461
177,555
898,555
347,040
Loss from operations
$
(533,492
)
$
(45,138
)
$
(586,766
)
$
(98,999
)
Interest income
1,718
1,957
2,749
4,381
Interest expense
(13,295
)
(11,712
)
(26,533
)
(20,903
)
Other (expense) income, net
(7,048
)
(766
)
(6,299
)
5,622
Loss before provision for income taxes
$
(552,117
)
$
(55,659
)
$
(616,849
)
$
(109,899
)
Provision for income taxes
(95
)
(3
)
(106
)
(9
)
Losses from equity method investments
-
(170
)
-
(301
)
Net Loss$
(552,212
)
$
(55,832
)
$
(616,955
)
$
(110,209
)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares
(11,540
)
(10,897
)
(39,347
)
(21,566
)
Cumulative Undeclared Dividends on Series C preferred shares
(668
)
(745
)
(1,174
)
(1,466
)
Net loss attributable to common shareholders, basic and diluted
(564,420
)
(67,474
)
(657,476
)
(133,241
)
Net loss per share attributable to common shareholders, basic and diluted$
(6.86
)
$
(1.07
)
$
(9.02
)
$
(2.11
)
Weighted-average shares outstanding used to compute net loss per share, basic and diluted
82,325
63,286
72,930
63,257
Comprehensive Loss, net of tax Net loss
$
(552,212
)
$
(55,832
)
$
(616,955
)
$
(110,209
)
Foreign currency translation adjustment
(43
)
53
(99
)
25
Comprehensive loss
$
(552,255
)
$
(55,779
)
$
(617,054
)
$
(110,184
)
Tempus AI, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
June 30, 2024 December 31, 2023 Assets Current Assets Cash and cash equivalents
$
478,811
$
165,767
Accounts receivable, net of allowances of $1,092 and $1,115 at June 30, 2024 and December 31, 2023, respectively
118,106
94,462
Inventory
32,690
28,845
Warrant asset
800
5,070
Prepaid expenses and other current assets
29,704
17,295
Marketable equity securities
11,255
31,807
Deferred offering costs
-
7,085
Total current assets
$
671,366
$
350,331
Property and equipment, net
60,539
61,681
Goodwill
73,345
73,354
Warrant asset, less current portion
1,500
4,930
Intangible assets, net
16,252
21,916
Investments and other assets
7,677
8,971
Warrant contract asset, less current portion
19,077
21,499
Operating lease right-of-use assets
13,994
20,530
Restricted cash
861
840
Total Assets
$
864,611
$
564,052
Liabilities, Convertible redeemable preferred stock, and Stockholders' equity (deficit) Current Liabilities Accounts payable
28,646
54,421
Accrued expenses
85,185
82,517
Deferred revenue
50,905
64,860
Other current liabilities
7,273
8,213
Operating lease liabilities
5,828
6,437
Accrued data licensing fees
3,727
6,382
Accrued dividends
-
9,797
Total current liabilities
$
181,564
$
232,627
Operating lease liabilities, less current portion
27,238
32,040
Convertible promissory note
180,648
193,124
Warrant liability
33,600
34,500
Other long-term liabilities
16,790
19,751
Interest payable
62,608
55,321
Long-term debt, net
261,853
256,541
Deferred revenue, less current portion
2,059
16,768
Total Liabilities
$
766,360
$
840,672
Commitments and contingencies (Note 7) Convertible redeemable preferred stock, $0.0001 par value, no and 69,803,765 shares authorized at June 30, 2024 and December 31, 2023, respectively; no and 63,525,953 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $0 and $1,130,429 at June 30, 2024 and December 31, 2023, respectively
$
-
$
1,105,543
Stockholders' equity (deficit) Class A Voting Common Stock, $0.0001 par value, 1,000,000,000 and 200,228,024 shares authorized at June 30, 2024 and December 31, 2023, respectively; 149,274,923 and 58,367,961 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively
$
15
$
6
Class B Voting Common Stock, $0.0001 par value, 5,500,000 and 5,374,899 shares authorized at June 30, 2024 and December 31, 2023, respectively; 5,043,789 and no shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively
1
-
Non-voting Common Stock, $0.0001 par value, no and 66,946,627 shares authorized at June 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at June 30, 2024, and 5,205,802 shares issued and 5,060,336 shares outstanding at December 31, 2023
-
0
Treasury Stock, 145,466 shares at June 30, 2024 and December 31, 2023, at cost
(3,602
)
(3,602
)
Additional Paid-In Capital
2,163,911
18,345
Accumulated Other Comprehensive (Loss) Income
(94
)
5
Accumulated deficit
(2,061,980
)
(1,396,917
)
Total Stockholders' equity (deficit)$
98,251
$
(1,382,163
)
Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity (deficit)$
864,611
$
564,052
Tempus AI, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands, except per share amounts)
Six Months Ended June 30,
2024
2023
Operating activities Net loss
$
(616,955
)
$
(110,209
)
Adjustments to reconcile net loss to net cash used in operating activities Change in fair value of warrant liability$
(900
)
$
(5,700
)
Stock-based compensation
488,313
-
Gain on warrant exercise
(173
)
-
Gain on marketable equity securities
(2,541
)
-
Amortization of original issue discount
691
489
Amortization of deferred financing fees
255
255
Change in fair value of contingent consideration
165
-
Amortization of warrant contract asset
2,422
3,307
Depreciation and amortization
18,348
16,185
Provision for bad debt expense
327
1,376
Change in fair value of warrant asset
7,700
-
Loss from equity-method investments
-
301
Amortization of finance right-of-use lease assets
-
190
Non-cash operating lease costs
3,252
3,382
Minimum accretion expense
92
187
Impairment of intangible assets
-
7,359
PIK interest added to principal
4,366
297
Change in assets and liabilities Accounts receivable
(23,971
)
(6,850
)
Inventory
(3,845
)
(5,101
)
Prepaid expenses and other current assets
(12,409
)
(1,634
)
Investments and other assets
1,294
(4,528
)
Accounts payable
(33,371
)
(4,195
)
Deferred revenue
(28,669
)
(19,974
)
Accrued data licensing fees
(2,749
)
(7,608
)
Accrued expenses & other
(2,805
)
8,125
Interest payable
7,287
7,611
Operating lease liabilities
(4,582
)
(4,352
)
Net cash used in operating activities$
(198,458
)
$
(121,087
)
Investing activities Purchases of property and equipment$
(14,116
)
$
(15,906
)
Proceeds from sale of marketable equity securities
23,098
-
Business combinations, net of cash acquired (Note 4)
-
(2,869
)
Net cash provided by (used in) investing activities$
8,982
$
(18,775
)
Financing activities Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions$
381,951
$
-
Tax withholding related to net share settlement of restricted stock units
(69,918
)
-
Issuance of Series G-5 Preferred Stock
199,750
-
Principal payments on finance lease liabilities
-
(192
)
Purchase of treasury stock
-
(3,602
)
Payment of deferred offering costs
(2,714
)
(151
)
Dividends paid
(5,625
)
(5,625
)
Proceeds from long-term debt, net of original issue discount
-
48,750
Payment of indemnity holdback related to acquisition
(813
)
-
Net cash provided by financing activities
$
502,631
$
39,180
Effect of foreign exchange rates on cash
$
(90
)
$
28
Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash
$
313,065
$
(100,654
)
Cash, cash equivalents and restricted cash, beginning of period
166,607
303,731
Cash, cash equivalents and restricted cash, end of period
$
479,672
$
203,077
Cash, Cash Equivalents and Restricted Cash are Comprised of: Cash and cash equivalents
$
478,811
$
202,266
Restricted cash and cash equivalents
861
811
Total cash, cash equivalents and restricted cash
$
479,672
$
203,077
Supplemental disclosure of cash flow information Cash paid during the year for interest
$
13,921
$
5,691
Cash paid for income taxes
$
89
$
41
Supplemental disclosure of noncash investing and financing activities Dividends payable
$
5,487
$
4,545
Purchases of property and equipment, accrued but not paid
$
1,108
$
2,952
Deferred offering costs, accrued but not yet paid
$
6,051
$
2,917
Redemption of convertible promissory note
$
12,476
$
13,926
Non-voting common stock issued in connection with business combinations
$
344
$
4,305
Operating lease liabilities arising from obtaining right-of-use assets
$
-
$
892
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering
$
1,348,809
$
-
Taxes related to net share settlement of restricted stock units not yet paid
$
164
$
-
Reclassificiation of deferred offering costs to additional paid-in capital upon initial public offering
$
12,347
$
-
Issuance of Series G-3 Preferred Stock
$
3,809
$
2,738
Issuance of Series G-4 Preferred Stock
$
611
$
-
Tempus AI, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands, except percentages and per share amounts)
Genomics Gross Profit & Gross Margin
Three Months Ended June 30,
Six Months Ended June 30,
2024
2023
2024
2023
Genomics revenue
$
112,324
$
91,924
$
214,893
$
173,982
Cost of revenues, genomics
68,324
46,961
121,159
92,241
Gross profit, genomics
$
44,000
$
44,963
$
93,734
$
81,741
Stock-based compensation expense
11,327
-
11,327
-
Employer payroll tax related to stock-based compensation
136
-
136
-
Non-GAAP gross profit, genomics
$
55,463
$
44,963
$
105,197
$
81,741
Genomics gross margin
39.2
%
48.9
%
43.6
%
47.0
%
Stock-based compensation expense
10.1
%
0.0
%
5.3
%
0.0
%
Employer payroll tax related to stock-based compensation
0.1
%
0.0
%
0.1
%
0.0
%
Non-GAAP gross margin, genomics
49.4
%
48.9
%
49.0
%
47.0
%
Data and Services Gross Profit & Gross MarginThree Months Ended June 30,
Six Months Ended June 30,
2024
2023
2024
2023
Data and services revenue
$
53,645
$
40,493
$
96,896
$
74,059
Cost of revenues, data and services
22,132
13,807
37,420
25,200
Gross profit, data and services
$
31,513
$
26,686
$
59,476
$
48,859
Stock-based compensation expense
7,229
-
7,229
-
Employer payroll tax related to stock-based compensation
119
-
119
-
Non-GAAP gross profit, data and services
$
38,861
$
26,686
$
66,824
$
48,859
Gross margin, data and services
58.7
%
65.9
%
61.4
%
66.0
%
Stock-based compensation expense
13.5
%
0.0
%
7.5
%
0.0
%
Employer payroll tax related to stock-based compensation
0.2
%
0.0
%
0.1
%
0.0
%
Non-GAAP gross margin, data and services
72.4
%
65.9
%
69.0
%
66.0
%
Total Gross Profit & Gross MarginThree Months Ended June 30,
Six Months Ended June 30,
2024
2023
2024
2023
Net revenue
$
165,969
$
132,417
$
311,789
$
248,041
Cost of revenues
90,456
60,768
158,579
117,441
Gross profit
$
75,513
$
71,649
$
153,210
$
130,600
Stock-based compensation expense
18,556
-
18,556
-
Employer payroll tax related to stock-based compensation
255
-
255
-
Non-GAAP gross profit
$
94,324
$
71,649
$
172,021
$
130,600
Gross margin
45.5
%
54.1
%
49.1
%
52.7
%
Stock-based compensation expense
11.2
%
0.0
%
6.0
%
0.0
%
Employer payroll tax related to stock-based compensation
0.2
%
0.0
%
0.1
%
0.0
%
Non-GAAP gross margin
56.8
%
54.1
%
55.2
%
52.7
%
Operating Expenses
Three Months Ended June 30, Six Months Ended June 30,
2024
2023
2024
2023
Technology Research and Development$
77,908
$
23,427
$
104,975
$
46,329
Stock-based compensation expense
50,434
-
50,434
-
Employer payroll tax related to stock-based compensation
1,248
-
1,248
-
Non-GAAP technology research and development$
26,226
$
23,427
$
53,293
$
46,329
Research and development$
68,025
$
22,171
$
92,365
$
43,034
Stock-based compensation expense
42,233
-
42,233
-
Employer payroll tax related to stock-based compensation
676
-
676
-
Non-GAAP research and development$
25,116
$
22,171
$
49,456
$
43,034
Selling, general and administrative$
463,072
$
71,189
$
542,636
$
140,236
Stock-based compensation expense
377,090
-
377,090
-
Employer payroll tax related to stock-based compensation
2,582
-
2,582
-
Non-GAAP selling, general and administrative$
83,400
$
71,189
$
162,964
$
140,236
Operating expenses$
609,005
$
116,787
$
739,976
$
229,599
Stock-based compensation expense
469,757
-
469,757
-
Employer payroll tax related to stock-based compensation
4,506
-
4,506
-
Non-GAAP operating expenses$
134,742
$
116,787
$
265,713
$
229,599
Earnings per Share
Three Months EndedJune 30, 2024 Six Months EndedJune 30, 2024 Net loss$
(552,212
)
$
(616,955
)
Fair value changes(1)
4,870
4,280
Stock-based compensation expense
488,313
488,313
Employer payroll tax related to stock-based compensation
4,762
4,762
G-4 Special Payment
2,250
2,250
Non-GAAP net loss
$
(52,017
)
$
(117,350
)
Non-GAAP net loss per share$
(0.63
)
$
(1.61
)
Weighted average common shares outstanding, basic and diluted
82,325
72,930
(1)Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities.
Adjusted EBITDA
Three Months Ended June 30, Six Months Ended June 30,
2024
2023
2024
2023
Net loss
$
(552,212
)
$
(55,832
)
$
(616,955
)
$
(110,209
)
Interest income
(1,718
)
(1,957
)
(2,749
)
(4,381
)
Interest expense
13,295
11,712
26,533
20,903
Depreciation
6,415
5,194
12,684
10,254
Amortization
2,744
3,043
5,664
5,931
Provision for income taxes
95
3
106
9
EBITDA
$
(531,381
)
$
(37,837
)
$
(574,717
)
$
(77,493
)
Losses on equity method investments
-
170
-
301
Fair value changes(1)
4,870
700
4,280
(5,700
)
Stock-based compensation expense
488,313
-
488,313
-
Employer payroll tax related to stock-based compensation
4,762
-
4,762
-
G-4 Special Payment
2,250
-
2,250
-
Adjusted EBITDA
$
(31,186
)
$
(36,967
)
$
(75,112
)
$
(82,892
)
(1)Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806760449/en/
Tempus Communications Erin Carron media@tempus.com
Tempus Investor Relations Elizabeth Krutoholow Elizabeth.krutoholow@tempus.com
H/Advisors Abernathy Dan Scorpio Dan.scorpio@h-advisors.global
1 Year Tempus AI Chart |
1 Month Tempus AI Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
